{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:19Z","timestamp":1791902659462,"version":"4.3.4"},"reference-count":19,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Long-standing alopecia areata is a therapeutically challenging subgroup lacking robust evidence regarding Janus kinase (JAK) inhibitors. This retrospective, single-centre study evaluated the efficacy and safety of baricitinib, tofacitinib or ritlecitinib in patients with current alopecia areata episodes lasting \u22658 years, treated between February 2021 and December 2025. Among 41 screened patients, 31 met the inclusion criteria (mean age 24.6\u00b110.1 years; mean episode duration 12.7\u00b14.6 years). The mean baseline SALT score was 62.8\u00b130.2, with 64.5% of patients presenting a baseline SALT score \u226550. At week 24 (n=29), 27.6% and 24.1% of patients achieved absolute SALT scores \u226420 and \u226410, respectively. Relative improvements (SALT30, SALT50 and SALT80) were observed in 48.3%, 31.0% and 24.1% of patients. Treatment discontinuation occurred in 58.1% (18\/31) of patients, primarily driven by a lack of efficacy (66.7% of these discontinuations). The most frequent adverse events were folliculitis (22.6%) and acne (12.9%). While the overall therapeutic response to JAK inhibitors remains limited in long-standing alopecia areata, a subset achieves clinically meaningful hair regrowth, supporting their use as a viable treatment option.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0453","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:04:57Z","timestamp":1782824697000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (\u22658 Years): A Real-world Observational Study"],"prefix":"10.2340","volume":"106","author":[{"given":"Xinchen","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0778-5270","authenticated-orcid":false,"given":"Yixia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aike","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"161094","doi-asserted-by":"crossref","unstructured":"Ungar B, Renert-Yuval Y, Dlova NC, Jabbari A, King B, Mesinkovska NA, et al. Alopecia areata. Nat Rev Dis Primers 2025; 11: 77.","DOI":"10.1038\/s41572-025-00664-9"},{"key":"161095","doi-asserted-by":"crossref","unstructured":"Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84: 370\u2013380.","DOI":"10.1016\/j.jaad.2020.04.138"},{"key":"161096","doi-asserted-by":"crossref","unstructured":"Glickman JW, Dubin C, Dahabreh D, Han J, Del Duca E, Estrada YD, et al. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy 2021; 76: 3053\u20133065.","DOI":"10.1111\/all.14814"},{"key":"161097","doi-asserted-by":"crossref","unstructured":"Deng S, Huang J, Li M, Jian J, Shi W. Complete blood collection-based systemic inflammation biomarkers as a severity biomarker in alopecia areata: A cross-sectional study. Acta Derm Venereol 2024; 104: adv40971.","DOI":"10.2340\/actadv.v104.40971"},{"key":"161098","doi-asserted-by":"crossref","unstructured":"Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. J Am Acad Dermatol 2026; 94: 161\u2013171.","DOI":"10.1016\/j.jaad.2025.09.044"},{"key":"161099","doi-asserted-by":"crossref","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687\u20131699.","DOI":"10.1056\/NEJMoa2110343"},{"key":"161100","doi-asserted-by":"crossref","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518\u20131529.","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"161101","doi-asserted-by":"crossref","unstructured":"Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol 2026; 94: 1134\u20131143.","DOI":"10.1016\/j.jaad.2025.11.070"},{"key":"161102","doi-asserted-by":"crossref","unstructured":"Davis KL, Messenger A, Va\u00f1\u00f3-Galv\u00e1n S, Tran H, Napatalung L, Hanson KA, et al. Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study. Clin Exp Dermatol 2025; 51: 42\u201351.","DOI":"10.1093\/ced\/llaf319"},{"key":"161103","doi-asserted-by":"crossref","unstructured":"Huang J, Jian J, Li M, Ji R, Tian T, Liang X, et al. Use of ritlecitinib in patients with alopecia areata refractory to tofacitinib or baricitinib: A single-center retrospective cohort study. J Am Acad Dermatol 2026; 94: 351\u2013353.","DOI":"10.1016\/j.jaad.2025.09.053"},{"key":"161104","doi-asserted-by":"crossref","unstructured":"Huang J, Jian J, Li M, Ji R, Tian T, Liang X, et al. Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors. J Am Acad Dermatol 2025; 93: 1236\u20131242.","DOI":"10.1016\/j.jaad.2025.07.008"},{"key":"161105","unstructured":"Huang JD, Shi W. Ritlecitinib in alopecia areata: A 24-week real-world experience contrasting JAK inhibitor-na\u00efve and JAK inhibitor-experienced patients. J Dermatol 2026."},{"key":"161106","doi-asserted-by":"crossref","unstructured":"Wang KX, Luo HG, Liu LP, Gao H, Song YY, Li D. Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. Front Pharmacol 2025; 16.","DOI":"10.3389\/fphar.2025.1577628"},{"key":"161107","doi-asserted-by":"crossref","unstructured":"Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015; 1: e1500973.","DOI":"10.1126\/sciadv.1500973"},{"key":"161108","doi-asserted-by":"crossref","unstructured":"Kim JE, Lee YJ, Park HR, Lee DG, Jeong KH, Kang H. The effect of JAK inhibitor on the survival, anagen re-entry, and hair follicle immune privilege restoration in human dermal papilla cells. IJMS 2020; 21: 5137.","DOI":"10.3390\/ijms21145137"},{"key":"161109","doi-asserted-by":"crossref","unstructured":"Raphael I, Joern RR, Forsthuber TG. Memory CD4+ T cells in immunity and autoimmune diseases. Cells 2020; 9: 531.","DOI":"10.3390\/cells9030531"},{"key":"161110","doi-asserted-by":"crossref","unstructured":"Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases. Front Immunol 2021; 12: 652191.","DOI":"10.3389\/fimmu.2021.652191"},{"key":"161111","doi-asserted-by":"crossref","unstructured":"Whiting DA. Histopathologic features of alopecia areata: A new look. Arch Dermatol 2003; 139: 1555\u20131559.","DOI":"10.1001\/archderm.139.12.1555"},{"key":"161112","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Barba D, Garc\u00eda-Moronta C, Haselgruber-de Francisco S, S\u00e1nchez-D\u00edaz M, Arias-Santiago S. Effectiveness and safety of Baricitinib in alopecia areata: A prospective cohort study. J Dermatolog Treat 2025; 36: 2583877.","DOI":"10.1080\/09546634.2025.2583877"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46419\/54605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46419\/54606","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46419\/54607","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46419\/54605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:06:16Z","timestamp":1782824776000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":19,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0453","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}